MDWD MediWound Ltd.

4.12
-0.05  -1%
Previous Close 4.17
Open 4.2
Price To Book 12.48
Market Cap 111976817
Shares 27,178,839
Volume 86,038
Short Ratio
Av. Daily Volume 117,769

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Further trial to be initiated mid-2019.
EscharEx
Chronic and other hard-to-heal wounds
BLA filing due 4Q 2019.
NexoBrid
Severe burns

Latest News

  1. Edited Transcript of MDWD earnings conference call or presentation 21-May-19 12:30pm GMT
  2. MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
  3. MediWound: 1Q Earnings Snapshot
  4. MediWound Reports First Quarter 2019 Financial Results
  5. MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time
  6. Vericel (VCEL) Q1 2019 Earnings Call Transcript
  7. MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
  8. Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know
  9. Edited Transcript of MDWD earnings conference call or presentation 25-Mar-19 12:30pm GMT
  10. MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018
  11. MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
  12. MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
  13. MediWound Announces Executive Leadership Changes
  14. Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
  15. Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?
  16. 4 Healthcare Stocks Looking to Set the Pace on Tuesday (1/22/19)
  17. MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns
  18. MediWound’s Late Stage Clinical Products Review, Analysts Review and Target
  19. Edited Transcript of MDWD earnings conference call or presentation 13-Nov-18 1:30pm GMT